Swedish Orphan Biovitrum Other Non-Current Liabilities 2019-2025 | BIOVF

Swedish Orphan Biovitrum other non-current liabilities for the quarter ending June 30, 2025 were $0.254B, a 10.58% decline year-over-year.

  • Swedish Orphan Biovitrum other non-current liabilities for 2024 were $0.274B, a 1.48% increase from 2023.
  • Swedish Orphan Biovitrum other non-current liabilities for 2023 were $0.27B, a 34.32% decline from 2022.
  • Swedish Orphan Biovitrum other non-current liabilities for 2022 were $0.411B, a 13.4% decline from 2021.

Swedish Orphan Biovitrum Other Non-Current Liabilities 2019-2025 | BIOVF

  • Swedish Orphan Biovitrum other non-current liabilities for 2024 were $0.274B, a 1.48% increase from 2023.
  • Swedish Orphan Biovitrum other non-current liabilities for 2023 were $0.27B, a 34.32% decline from 2022.
  • Swedish Orphan Biovitrum other non-current liabilities for 2022 were $0.411B, a 13.4% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$249.5B
Amgen (AMGN)$159.2B
Gilead Sciences (GILD)$144.1B
Vertex Pharmaceuticals (VRTX)$101.9B
Bristol Myers Squibb (BMY)$98.6B
GSK (GSK)$81.7B
CSL (CSLLY)$69.9B
Regeneron Pharmaceuticals (REGN)$63.4B
Alnylam Pharmaceuticals (ALNY)$61.3B
Argenex SE (ARGX)$40.6B
Insmed (INSM)$28B
BioNTech SE (BNTX)$26.6B
Royalty Pharma (RPRX)$21.2B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.9B
Genmab (GNMSF)$16.1B
Genmab (GMAB)$15.7B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.8B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.4B
Moderna (MRNA)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.8B
Bio-Techne Corp (TECH)$8.5B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8B
Guardant Health (GH)$7.6B